-
公开(公告)号：US20210253637A1
公开(公告)日：2021-08-19
申请号：US17238840
申请日：2021-04-23
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Toni WEINSCHENK , Oliver SCHOOR , Claudia TRAUTWEIN , Norbert HILF , Steffen WALTER , Harpreet SINGH
IPC: C07K7/06 , A61K39/00 , C07K7/08 , A61K35/17 , G01N33/574 , C07K14/74 , A61M5/00 , C12N5/0783
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US20160355550A1
公开(公告)日：2016-12-08
申请号：US15226002
申请日：2016-08-02
Applicant: immatics biotechnologies GmbH
Inventor： Toni WEINSCHENK , Oliver SCHOOR , Claudia TRAUTWEIN , Norbert HILF , Steffen WALTER , Harpreet SINGH
CPC classification number: C07K7/06 , A61K35/17 , A61K38/00 , A61K39/0011 , A61K2039/5154 , A61K2039/5158 , A61K2039/53 , A61K2039/55511 , A61K2039/55516 , A61K2039/55522 , A61K2039/55561 , A61K2039/55588 , A61K2039/572 , A61K2039/605 , A61K2039/6081 , A61K2039/6093 , A61M5/002 , C07K7/08 , C07K14/70539 , C07K2319/00 , C07K2319/40 , C12N5/0638 , C12N2501/50 , G01N33/57492 , Y02A50/472
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US20140271692A1
公开(公告)日：2014-09-18
申请号：US14138421
申请日：2013-12-23
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Harpreet SINGH , Steffen WALTER , Toni WEINSCHENK , Norbert HILF , Oliver SCHOOR , Claudia TRAUTWEIN
CPC classification number: A61K39/0011 , A61K35/17 , A61K2039/5158 , A61K2039/572 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/4748 , C07K14/495 , C07K14/7051 , C07K16/40 , C07K19/00 , C07K2317/34 , C07K2319/00 , C12N5/0638 , C12N9/0036 , C12N9/13 , C12N2502/1157 , C12Y208/02011
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumour cells which can be used in vaccine compositions for eliciting anti-tumour immune responses.
Abstract translation: 本发明涉及用于免疫治疗方法的肽，核酸和细胞。 特别地，本发明涉及癌症的免疫治疗。 本发明还涉及肿瘤相关的T辅助细胞肽表位，其单独或与作为刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分的其它肿瘤相关肽组合。 本发明涉及可用于引发抗肿瘤免疫应答的疫苗组合物中的HLA I类和II类分子的新型肽序列及其变体。
-
公开(公告)号：US20230089882A1
公开(公告)日：2023-03-23
申请号：US17851417
申请日：2022-06-28
Applicant: Immatics Biotechnologies GmbH
Inventor： Sabrina KUTTRUFF-COQUI , Toni WEINSCHENK , Jens FRITSCHE , Steffen WALTER , Norbert HILF , Oliver SCHOOR , Colette SONG , Harpreet SINGH
IPC: A61K39/00 , C07K14/47 , C07K14/705 , A61K35/17 , C07K7/06 , C07K7/08 , C07K14/74 , C07K16/28 , C12Q1/6886
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US20160376313A1
公开(公告)日：2016-12-29
申请号：US15226081
申请日：2016-08-02
Applicant: immatics biotechnologies GmbH
Inventor： Toni WEINSCHENK , Oliver SCHOOR , Claudia TRAUTWEIN , Norbert HILF , Steffen WALTER , Harpreet SINGH
CPC classification number: C07K7/06 , A61K35/17 , A61K38/00 , A61K39/0011 , A61K2039/5154 , A61K2039/5158 , A61K2039/53 , A61K2039/55511 , A61K2039/55516 , A61K2039/55522 , A61K2039/55561 , A61K2039/55588 , A61K2039/572 , A61K2039/605 , A61K2039/6081 , A61K2039/6093 , A61M5/002 , C07K7/08 , C07K14/70539 , C07K2319/00 , C07K2319/40 , C12N5/0638 , C12N2501/50 , G01N33/57492 , Y02A50/472
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
Patent Agency Ranking
公开(公告)号：US20160175357A1
公开(公告)日：2016-06-23
申请号：US14865278
申请日：2015-09-25
Applicant: immatics biotechnologies GmbH
Inventor： Toni WEINSCHENK , Oliver SCHOOR , Claudia TRAUTWEIN , Norbert HILF , Steffen WALTER , Harpreet SINGH
IPC: A61K35/17 , C12N5/0783 , C07K14/47
CPC classification number: A61K35/17 , A61K38/00 , C07K7/06 , C07K7/08 , C07K14/4748 , C12N5/0638
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US20220362363A1
公开(公告)日：2022-11-17
申请号：US17852207
申请日：2022-06-28
Applicant: Immatics Biotechnologies GmbH
Inventor： Sabrina KUTTRUFF-COQUI , Toni WEINSCHENK , Jens FRITSCHE , Steffen WALTER , Norbert HILF , Oliver SCHOOR , Colette SONG , Harpreet SINGH
IPC: A61K39/00 , C07K14/47 , C07K14/705 , A61K35/17 , C07K7/06 , C07K7/08 , C07K14/74 , C07K16/28 , C12Q1/6886
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US20220362362A1
公开(公告)日：2022-11-17
申请号：US17852205
申请日：2022-06-28
Applicant: Immatics Biotechnologies GmbH
Inventor： Sabrina KUTTRUFF-COQUI , Toni WEINSCHENK , Jens FRITSCHE , Steffen WALTER , Norbert HILF , Oliver SCHOOR , Colette SONG , Harpreet SINGH
IPC: A61K39/00 , C07K14/47 , C07K14/705 , A61K35/17 , C07K7/06 , C07K7/08 , C07K14/74 , C07K16/28 , C12Q1/6886
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US20210393754A1
公开(公告)日：2021-12-23
申请号：US17390584
申请日：2021-07-30
Applicant: Immatics Biotechnologies GmbH
Inventor： Sabrina KUTTRUFF-COQUI , Toni WEINSCHENK , Jens FRITSCHE , Steffen WALTER , Norbert HILF , Oliver SCHOOR , Colette SONG , Harpreet SINGH
IPC: A61K39/00 , C07K14/47 , C07K14/705 , A61K35/17 , C07K7/06 , C07K7/08 , C07K14/74 , C07K16/28 , C12Q1/6886
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US20210261614A1
公开(公告)日：2021-08-26
申请号：US17238787
申请日：2021-04-23
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Toni WEINSCHENK , Oliver SCHOOR , Claudia TRAUTWEIN , Norbert HILF , Steffen WALTER , Harpreet SINGH
IPC: C07K7/06 , A61K39/00 , C07K7/08 , A61K35/17 , G01N33/574 , C07K14/74 , A61M5/00 , C12N5/0783
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
-
-
-
-
-
-
-
-
Search Results
27
records
(took 0.016 seconds)
